ArticleProceedings of the National Academy of Sciences of the United States of America2010
Prothymosin-alpha inhibits HIV-1 via Toll-like receptor 4-mediated type I interferon induction.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 80 citations in OpenAlex.
- Characterisation of airway inflammation and proteomes associated with cystic fibrosis-related diabetes.ERJ open research · 2025Article
- Current insight into HIV-1 persistence from single-cell transcriptome profiling in acutely treated cohorts of infection.Current opinion in HIV and AIDS · 2025Review
- Single-cell RNA sequencing combined with proteomics of infected macrophages reveals prothymosin-α as a target for treatment of apical periodontitis.Journal of advanced research · 2024Article
- Article
- Lumbosacral spinal proteomic changes during PAR4-induced persistent bladder pain.Neuroscience letters · 2024Article
- MiR-155 Negatively Regulates Anti-Viral Innate Responses among HIV-Infected Progressors.Viruses · 2023Article
- Single-cell transcriptomics identifies prothymosin α restriction of HIV-1 in vivo.Science translational medicine · 2023Article
- Review
- Immunogenic Cell Death, DAMPs and Prothymosin α as a Putative Anticancer Immune Response Biomarker.Cells · 2022Review
- Involvement of SNARE Protein Interaction for Non-classical Release of DAMPs/Alarmins Proteins, Prothymosin Alpha and S100A13.Cellular and molecular neurobiology · 2021Article
- The CD8Microbiology and molecular biology reviews : MMBR · 2021Review
- Cystic Fibrosis-Related Diabetes (CFRD): Overview of Associated Genetic Factors.Diagnostics (Basel, Switzerland) · 2021Review
- Genetic Modifiers of Cystic Fibrosis-Related Diabetes Have Extensive Overlap With Type 2 Diabetes and Related Traits.The Journal of clinical endocrinology and metabolism · 2020Article
- Antitumor Reactive T-Cell Responses Are Enhanced In Vivo by DAMP Prothymosin Alpha and Its C-Terminal Decapeptide.Cancers · 2019Article
- Article
- The interactome and proteomic responses of ALKBH7 in cell lines by in-depth proteomics analysis.Proteome science · 2019Article
- A fragment of the alarmin prothymosin α as a novel biomarker in murine models of bacteria-induced sepsis.Oncotarget · 2017Article
- Global Characterization of Protein Secretion from Human Macrophages Following Non-canonical Caspase-4/5 Inflammasome Activation.Molecular & cellular proteomics : MCP · 2017Article
- Porphyromonas gingivalis-mediated signaling through TLR4 mediates persistent HIV infection of primary macrophages.Virology · 2016Article
- Prothymosin Alpha and Immune Responses: Are We Close to Potential Clinical Applications?Vitamins and hormones · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
Induction of type I interferons (IFN) is a central feature of innate immune responses to microbial pathogens and is mediated via Toll-like receptor (TLR)-dependent and -independent pathways. Prothymosin-alpha (ProTalpha), a small acidic protein produced and released by CD8(+) T cells, inhibits HIV-1, although the mechanism for its antiviral activity was not known. We demonstrate that exogenous ProTalpha acts as a ligand for TLR4 and stimulates type I IFN production to potently suppress HIV-1 after entry into cells. These activities are induced by native and recombinant ProTalpha, retained by an acidic peptide derived from ProTalpha, and lost in the absence of TLR4. Furthermore, we demonstrate that ProTalpha accounts for some of the soluble postintegration HIV-1 inhibitory activity long ascribed to CD8(+) cells. Thus, a protein produced by CD8(+) T cells of the adaptive immune system can exert potent viral suppressive activity through an innate immune response. Understanding the mechanism of IFN induction by ProTalpha may provide therapeutic leads for IFN-sensitive viruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.